Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Net Cash Flow: 2017-2025

Historic Net Cash Flow for Protagonist Therapeutics (PTGX) over the last 9 years, with Sep 2025 value amounting to -$54.8 million.

  • Protagonist Therapeutics' Net Cash Flow rose 75.58% to -$54.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.3 million, marking a year-over-year increase of 82.55%. This contributed to the annual value of -$89.5 million for FY2024, which is 246.73% down from last year.
  • Per Protagonist Therapeutics' latest filing, its Net Cash Flow stood at -$54.8 million for Q3 2025, which was down 289.37% from $29.0 million recorded in Q2 2025.
  • Over the past 5 years, Protagonist Therapeutics' Net Cash Flow peaked at $183.1 million during Q2 2024, and registered a low of -$224.5 million during Q3 2024.
  • Over the past 3 years, Protagonist Therapeutics' median Net Cash Flow value was -$4.9 million (recorded in 2023), while the average stood at -$1.1 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first plummeted by 4,524.55% in 2024, then spiked by 399.48% in 2025.
  • Protagonist Therapeutics' Net Cash Flow (Quarterly) stood at $3.1 million in 2021, then slumped by 975.43% to -$27.1 million in 2022, then crashed by 61.34% to -$43.8 million in 2023, then increased by 22.67% to -$33.9 million in 2024, then surged by 75.58% to -$54.8 million in 2025.
  • Its last three reported values are -$54.8 million in Q3 2025, $29.0 million for Q2 2025, and $42.4 million during Q1 2025.